. 2019 Jan 15;316(5):E749–E772. doi: 10.1152/ajpendo.00343.2018

Table 5.

Estimated femoral structural mechanical properties from WT and Nmp4^−/− mice treated with vehicle, raloxifene, parathyroid hormone, and parathyroid hormone + raloxifene

	Yield Force, N	Ultimate Force, N	Displacement to yield, µm	Postyield Displacement, µm	Total Displacement, µm
Group
WT VEH	10.08 ± 0.99	13.52 ± 1.16	162.51 ± 12.49	843.05 ± 320.03	1,005.56 ± 312.72
Nmp4⁻^/⁻ VEH	11.65 ± 2.44	14.27 ± 0.92	172.64 ± 26.99	619.27 ± 224.97	792.43 ± 217.81
WT RAL	11.19 ± 0.20	14.67 ± 0.41	168.22 ± 12.96	689.72 ± 208.95	861.14 ± 199.79
Nmp4⁻^/⁻ RAL	15.22 ± 1.20	15.22 ± 1.20	173.53 ± 15.73	594.32 ± 202.51	769.68 ± 193.22
WT PTH	11.04 ± 2.06	16.94 ± 1.67	163.51 ± 28.73	711.57 ± 297.33	875.08 ± 288.88
Nmp4⁻^/⁻ PTH	11.24 ± 1.79	17.06 ± 1.38	146.49 ± 18.81	742 ± 255.98	894.10 ± 252.89
WT PTH + RAL	11.50 ± 1.18	18.38 ± 2.31	152.56 ± 34.07	540.96 ± 205.28	693.53 ± 202.12
Nmp4⁻^/⁻ PTH + RAL	13.66 ± 2.51	19.43 ± 2.18	152.09 ± 8.08	458.30 ± 166.36	578.77 ± 109.62
Two-way ANOVA genotype	G: P = 0.0037	G: P = 0.0680	G: P = 0.9119	G: P = 0.0610	G: P = 0.0379
	Nmp4⁻^/⁻: 12.22^a				WT: 858.83^a
	WT: 10.95^b				Nmp4^-/⁻: 758.74^b
Two-way ANOVA treatment	T: P = 0.0243	T: P < 0.0001	T: P = 0.0137	T: P = 0.0028	T: P = 0.0005
	P + R: 12.58^a	P + R: 18.91^a	R: 170.87^a	V: 731.16^a	V: 898.99^a
	R: 11.76^a,^b	P: 17.00^b	V: 167.57^a,^b	P: 726.78^a	P: 884.59^a
	P: 11.14^a,^b	R: 14.95^c	P: 155.00^a,^b	R: 642.02^a,^b	R: 815.4^a
	V: 10.87^b	V: 13.90^c	P + R: 152.33^b	P + R: 499.64^b	P + R: 636.15^b
Two-way ANOVA G × T	G × T: P = 0.4051	G × T: P = 0.7791	G × T: P = 0.1830	G × T: P = 0.3475	G × T: P = 0.3910
	Stiffness, N/mm	Work to Yield, mJ	Post Yield Work, mJ	Total Work, mJ
Group
WT VEH	95.73 ± 6.19	0.92 ± 0.16	8.01 ± 2.16	8.93 ± 2.05
Nmp4⁻^/⁻ VEH	104.39 ± 10.17	1.05 ± 0.31	7.53 ± 2.63	8.64 ± 2.63
WT RAL	106.07 ± 12.65	1.05 ± 0.08	8.10 ± 1.91	9.15 ± 1.90
Nmp4⁻^/⁻ RAL	105.42 ± 16.10	1.19 ± 0.34	7.63 ± 2.14	8.91 ± 2.17
WT PTH	120.02 ± 22.68	0.94 ± 0.32	9.44 ± 2.92	10.38 ± 2.76
Nmp4⁻^/⁻ PTH	121.91 ± 16.51	0.89 ± 0.23	10.24 ± 2.81	11.18 ± 2.74
WT PTH + RAL	130.49 ± 10.66	0.92 ± 0.29	7.98 ± 1.97	8.97 ± 1.85
Nmp4⁻^/⁻ PTH + RAL	132.83 ± 17.91	1.25 ± 0.45	7.69 ± 2.61	8.94 ± 2.45
Two-way ANOVA genotype	G: P = 0.3316	G: P = 0.0315	G: P = 0.8291	G: P = 0.8989
		Nmp4^-/⁻: 1.10^a
		WT: 0.96^b
Two-way ANOVA treatment	T: P < 0.0001	T: P = 0.0985	T: P = 0.0103	T: P = 0.0159
	P + R: 131.66^a		P: 9.84^a	P: 10.78^a
	P: 120.97^a		R: 7.87^b	R: 9.^a,^b
	R: 105.74^b		P + R: 7.83^b	P + R: 8.95^b
	V: 100.06^b		V: 7.77^b	V: 8.79^b
Two-way ANOVA G × T	G × T: P = 0.7575	G × T: P = 0.2168	G × T: P = 0.7762	G × T: P = 0.8461

Data represent average ± SD; n = 7–14 mice/group. Nmp4, nuclear matrix protein 4; WT, wild type; V/VEH, vehicle; R/RAL, raloxifene; P/PTH, parathyroid hormone; P/PTH + R/RAL, and parathyroid hormone + raloxifene; BV/TV, bone volume per total volume. Statistical analyses were performed using two-way ANOVA tests setting genotype (G) and treatment (T) as the independent variables. Statistical significance was set at P ≤ 0.05. The statistical results list the cohorts by genotype, treatment, and genotype × treatment.

^{a b c}Cohorts not connected by the same letter are statistically different; the average value of the specific parameter precedes the letter.